Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 2Active not recruiting 2

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Glioblastoma 1Colorectal Neoplasms 1

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 11Cyclophosphamide 10Biological Therapy 9Drug Therapy 8Dexamethasone 7Biopsy 7antineoplaston A10 6Nivolumab 6Complementary Therapies 6fludarabine 5antineoplaston AS 2-1 5aldesleukin 5Ipilimumab 5Etoposide 5Doxorubicin 5Cisplatin 5atezolizumab 4Vincristine 4Surgical Procedures, Operative 4Rituximab 4Paclitaxel 4Chemotherapy, Adjuvant 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4venetoclax 3olaparib 3dexamethasone acetate 3dexamethasone 21-phosphate 3copanlisib 3auricularum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × NIH × Tiragolumab × Clear all
NCT06603818 2026-02-19

Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT06328036 2024-12-30

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡